> top > docs > PubMed:24652679 > annotations

PubMed:24652679 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 11-17 UBERON:0027368 denotes matrix
T2 18-42 GO:0008237 denotes metalloprotease activity
T3 47-58 P28798 denotes progranulin
T4 47-58 P28799 denotes progranulin
T6 47-58 PR:000008271 denotes progranulin
T7 47-58 P28797 denotes progranulin
T9 47-58 P23785 denotes progranulin
T5 47-58 D000077153 denotes progranulin
T8 47-58 D000077153 denotes progranulin
T11 126-133 6308 denotes leucine
T12 126-133 SO:0001437 denotes leucine
T10 126-133 CHEBI:15603 denotes leucine
T13 126-133 D007930 denotes leucine
T14 126-133 CHEBI:25017 denotes leucine
T15 126-133 D007930 denotes leucine
T16 139-145 SO:0001068 denotes repeat
T21 190-209 D010300 denotes Parkinson's disease
T22 190-209 D010300 denotes Parkinson's disease
T26 222-229 6308 denotes Leucine
T27 222-229 SO:0001437 denotes Leucine
T25 222-229 CHEBI:15603 denotes Leucine
T28 222-229 D007930 denotes Leucine
T29 222-229 CHEBI:25017 denotes Leucine
T30 222-229 D007930 denotes Leucine
T31 235-241 SO:0001068 denotes repeat
T32 252-257 PR:Q5S006 denotes LRRK2
T33 252-257 PR:000003033 denotes LRRK2
T34 252-257 PR:Q5S007 denotes LRRK2
T35 288-293 UBERON:6110636 denotes brain
T36 288-293 UBERON:0000955 denotes brain
T37 370-390 D009414 denotes neurotrophic protein
T38 370-390 D009414 denotes neurotrophic protein
T42 383-390 PR:000000001 denotes protein
T39 383-390 GO:0003675 denotes protein
T43 383-390 SO:0000104 denotes protein
T44 391-402 P28798 denotes progranulin
T45 391-402 P28799 denotes progranulin
T47 391-402 PR:000008271 denotes progranulin
T48 391-402 P28797 denotes progranulin
T50 391-402 P23785 denotes progranulin
T46 391-402 D000077153 denotes progranulin
T49 391-402 D000077153 denotes progranulin
T51 404-408 P28798 denotes PGRN
T52 404-408 P28799 denotes PGRN
T53 404-408 PR:000008271 denotes PGRN
T54 404-408 P28797 denotes PGRN
T55 404-408 P23785 denotes PGRN
T58 451-477 D019636 denotes neurodegenerative diseases
T59 451-477 D019636 denotes neurodegenerative diseases
T60 497-501 P28798 denotes PGRN
T61 497-501 P28799 denotes PGRN
T62 497-501 PR:000008271 denotes PGRN
T63 497-501 P28797 denotes PGRN
T64 497-501 P23785 denotes PGRN
T65 538-556 D017077 denotes conditioned medium
T66 560-565 PR:Q5S006 denotes LRRK2
T67 560-565 PR:000003033 denotes LRRK2
T68 560-565 PR:Q5S007 denotes LRRK2
T69 581-586 10090 denotes mouse
T70 581-586 D051379 denotes mouse
T71 616-625 CL:0000129 denotes microglia
T75 675-688 PR:000001091 denotes interleukin-1
T74 675-688 D007375 denotes interleukin-1
T76 675-688 D007375 denotes interleukin-1
T77 694-706 CL:0000312 denotes keratinocyte
T78 766-770 P28798 denotes PGRN
T79 766-770 P28799 denotes PGRN
T80 766-770 PR:000008271 denotes PGRN
T81 766-770 P28797 denotes PGRN
T82 766-770 P23785 denotes PGRN
T83 825-830 D006801 denotes human
T84 857-871 D058070 denotes presymptomatic
T85 857-871 D058070 denotes presymptomatic
T86 872-877 PR:Q5S006 denotes LRRK2
T87 872-877 PR:000003033 denotes LRRK2
T88 872-877 PR:Q5S007 denotes LRRK2
T89 886-894 SO:0000109 denotes mutation
T90 895-903 CHEBI:78059 denotes carriers
T91 980-986 UBERON:0027368 denotes matrix
T92 1004-1007 CHEBI:340824 denotes MMP
T95 1004-1007 CHEBI:59761 denotes MMP
T96 1004-1010 PR:P08253 denotes MMP) 2
T97 1004-1010 Q9GLE5 denotes MMP) 2
T98 1004-1010 P08253 denotes MMP) 2
T99 1004-1010 Q90611 denotes MMP) 2
T101 1004-1010 PR:Q8MPP3 denotes MMP) 2
T102 1004-1010 P33436 denotes MMP) 2
T103 1004-1010 PR:Q90611 denotes MMP) 2
T104 1004-1010 PR:P33436 denotes MMP) 2
T105 1004-1010 PR:000010479 denotes MMP) 2
T106 1004-1010 PR:P33434 denotes MMP) 2
T107 1004-1010 P33434 denotes MMP) 2
T108 1004-1010 P50757 denotes MMP) 2
T100 1004-1010 GO:0004228 denotes MMP) 2
T109 1030-1033 CHEBI:340824 denotes MMP
T112 1030-1033 CHEBI:59761 denotes MMP
T113 1030-1035 PR:P50282 denotes MMP 9
T114 1030-1035 PR:P14780 denotes MMP 9
T115 1030-1035 P14780 denotes MMP 9
T116 1030-1035 PR:P41245 denotes MMP 9
T117 1030-1035 P41246 denotes MMP 9
T118 1030-1035 P41245 denotes MMP 9
T119 1030-1035 PR:P52176 denotes MMP 9
T120 1030-1035 P50282 denotes MMP 9
T122 1030-1035 PR:000010491 denotes MMP 9
T123 1030-1035 P52176 denotes MMP 9
T124 1030-1035 O18733 denotes MMP 9
T121 1030-1035 GO:0004229 denotes MMP 9
T125 1049-1054 PR:Q5S006 denotes LRRK2
T126 1049-1054 PR:000003033 denotes LRRK2
T127 1049-1054 PR:Q5S007 denotes LRRK2
T128 1070-1079 CL:0000129 denotes microglia
T131 1119-1122 PR:O04529 denotes MMP
T129 1119-1122 CHEBI:340824 denotes MMP
T132 1119-1122 CHEBI:59761 denotes MMP
T130 1119-1122 GO:0004235 denotes MMP
T134 1134-1140 PR:000001360 denotes ICAM-5
T135 1134-1140 Q9UMF0 denotes ICAM-5
T136 1134-1140 Q60625 denotes ICAM-5
T137 1134-1140 PR:Q60625 denotes ICAM-5
T138 1134-1140 Q28730 denotes ICAM-5
T139 1134-1140 PR:Q9UMF0 denotes ICAM-5
T141 1147-1156 P37379 denotes synuclein
T140 1147-1156 D051843 denotes synuclein
T142 1183-1188 PR:Q5S006 denotes LRRK2
T143 1183-1188 PR:000003033 denotes LRRK2
T144 1183-1188 PR:Q5S007 denotes LRRK2
T145 1204-1209 10090 denotes mouse
T146 1204-1209 D051379 denotes mouse
T147 1210-1215 UBERON:6110636 denotes brain
T148 1210-1215 UBERON:0000955 denotes brain
T151 1249-1252 PR:O04529 denotes MMP
T149 1249-1252 CHEBI:340824 denotes MMP
T152 1249-1252 CHEBI:59761 denotes MMP
T150 1249-1252 GO:0004235 denotes MMP
T153 1263-1267 P28798 denotes PGRN
T154 1263-1267 P28799 denotes PGRN
T155 1263-1267 PR:000008271 denotes PGRN
T156 1263-1267 P28797 denotes PGRN
T157 1263-1267 P23785 denotes PGRN
T158 1297-1316 UBERON:0001359 denotes cerebrospinal fluid
T160 1320-1334 D058070 denotes presymptomatic
T161 1320-1334 D058070 denotes presymptomatic
T162 1335-1340 PR:Q5S006 denotes LRRK2
T163 1335-1340 PR:000003033 denotes LRRK2
T164 1335-1340 PR:Q5S007 denotes LRRK2
T165 1348-1352 PR:000005054 denotes mice
T167 1348-1352 O89094 denotes mice
T166 1348-1352 D051379 denotes mice
T168 1348-1352 10095 denotes mice
T169 1362-1366 P28798 denotes PGRN
T170 1362-1366 P28799 denotes PGRN
T171 1362-1366 PR:000008271 denotes PGRN
T172 1362-1366 P28797 denotes PGRN
T173 1362-1366 P23785 denotes PGRN
T174 1416-1420 PR:000005054 denotes mice
T176 1416-1420 O89094 denotes mice
T175 1416-1420 D051379 denotes mice
T177 1416-1420 10095 denotes mice
T178 1431-1435 P28798 denotes PGRN
T179 1431-1435 P28799 denotes PGRN
T180 1431-1435 PR:000008271 denotes PGRN
T181 1431-1435 P28797 denotes PGRN
T182 1431-1435 P23785 denotes PGRN
T183 1470-1489 UBERON:0001359 denotes cerebrospinal fluid
T185 1514-1519 PR:Q5S006 denotes LRRK2
T186 1514-1519 PR:000003033 denotes LRRK2
T187 1514-1519 PR:Q5S007 denotes LRRK2
T188 1661-1666 UBERON:6110636 denotes brain
T189 1661-1666 UBERON:0000955 denotes brain
T194 1740-1759 D010300 denotes Parkinson's disease
T195 1740-1759 D010300 denotes Parkinson's disease
T198 1770-1775 PR:Q5S006 denotes LRRK2
T199 1770-1775 PR:000003033 denotes LRRK2
T200 1770-1775 PR:Q5S007 denotes LRRK2

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-155 Sentence denotes Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
T2 156-316 Sentence denotes Increasing evidence suggests that Parkinson's disease (PD)-linked Leucine-rich repeat kinase 2 (LRRK2) has a role in peripheral and brain-resident immune cells.
T3 317-478 Sentence denotes Furthermore, dysregulation of the anti-inflammatory, neurotrophic protein progranulin (PGRN) has been demonstrated in several chronic neurodegenerative diseases.
T4 479-755 Sentence denotes Here we show that PGRN levels are significantly reduced in conditioned medium of LRRK2(R1441G) mutant mouse fibroblasts, leukocytes, and microglia, whereas levels of proinflammatory factors, like interleukin-1β and keratinocyte-derived chemokine, were significantly increased.
T5 756-949 Sentence denotes Decreased PGRN levels were also detected in supernatants of cultured human fibroblasts isolated from presymptomatic LRRK2(G2019S) mutation carriers, while mitochondrial function was unaffected.
T6 950-1080 Sentence denotes Furthermore, medium levels of matrix metalloprotease (MMP) 2 increased, whereas MMP 9 decreased in LRRK2(R1441G) mutant microglia.
T7 1081-1262 Sentence denotes Increased proteolytic cleavage of the MMP substrates ICAM-5 and α-synuclein in synaptoneurosomes from LRRK2(R1441G) mutant mouse brain indicates increased net synaptic MMP activity.
T8 1263-1421 Sentence denotes PGRN levels were decreased in the cerebrospinal fluid of presymptomatic LRRK2 mutant mice, whereas PGRN levels were increased in aged symptomatic mutant mice.
T9 1422-1595 Sentence denotes Notably, PGRN levels were also increased in the cerebrospinal fluid of PD patients carrying LRRK2 mutations, but not in idiopathic PD patients and in healthy control donors.
T10 1596-1786 Sentence denotes Our data suggest that proinflammatory activity of peripheral and brain-resident immune cells may particularly contribute to the early stages of Parkinson's disease caused by LRRK2 mutations.
T1 0-155 Sentence denotes Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
T2 156-316 Sentence denotes Increasing evidence suggests that Parkinson's disease (PD)-linked Leucine-rich repeat kinase 2 (LRRK2) has a role in peripheral and brain-resident immune cells.
T3 317-478 Sentence denotes Furthermore, dysregulation of the anti-inflammatory, neurotrophic protein progranulin (PGRN) has been demonstrated in several chronic neurodegenerative diseases.
T4 479-755 Sentence denotes Here we show that PGRN levels are significantly reduced in conditioned medium of LRRK2(R1441G) mutant mouse fibroblasts, leukocytes, and microglia, whereas levels of proinflammatory factors, like interleukin-1β and keratinocyte-derived chemokine, were significantly increased.
T5 756-949 Sentence denotes Decreased PGRN levels were also detected in supernatants of cultured human fibroblasts isolated from presymptomatic LRRK2(G2019S) mutation carriers, while mitochondrial function was unaffected.
T6 950-1080 Sentence denotes Furthermore, medium levels of matrix metalloprotease (MMP) 2 increased, whereas MMP 9 decreased in LRRK2(R1441G) mutant microglia.
T7 1081-1262 Sentence denotes Increased proteolytic cleavage of the MMP substrates ICAM-5 and α-synuclein in synaptoneurosomes from LRRK2(R1441G) mutant mouse brain indicates increased net synaptic MMP activity.
T8 1263-1421 Sentence denotes PGRN levels were decreased in the cerebrospinal fluid of presymptomatic LRRK2 mutant mice, whereas PGRN levels were increased in aged symptomatic mutant mice.
T9 1422-1595 Sentence denotes Notably, PGRN levels were also increased in the cerebrospinal fluid of PD patients carrying LRRK2 mutations, but not in idiopathic PD patients and in healthy control donors.
T10 1596-1786 Sentence denotes Our data suggest that proinflammatory activity of peripheral and brain-resident immune cells may particularly contribute to the early stages of Parkinson's disease caused by LRRK2 mutations.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 391-402 gene:2896 denotes progranulin
T1 451-477 disease:C0524851 denotes neurodegenerative diseases
T2 404-408 gene:2896 denotes PGRN
T3 451-477 disease:C0524851 denotes neurodegenerative diseases
R1 T0 T1 associated_with progranulin,neurodegenerative diseases
R2 T2 T3 associated_with PGRN,neurodegenerative diseases

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 190-199 HP_0001300 denotes Parkinson
T2 911-924 HP_0001427 denotes mitochondrial
T3 1740-1749 HP_0001300 denotes Parkinson

Allie

Id Subject Object Predicate Lexical cue
SS1_24652679_1_0 190-209 expanded denotes Parkinson's disease
SS2_24652679_1_0 211-213 abbr denotes PD
SS1_24652679_1_1 222-250 expanded denotes Leucine-rich repeat kinase 2
SS2_24652679_1_1 252-257 abbr denotes LRRK2
SS1_24652679_2_0 391-402 expanded denotes progranulin
SS2_24652679_2_0 404-408 abbr denotes PGRN
SS1_24652679_5_0 980-1002 expanded denotes matrix metalloprotease
SS2_24652679_5_0 1004-1007 abbr denotes MMP
AE1_24652679_1_0 SS1_24652679_1_0 SS2_24652679_1_0 abbreviatedTo Parkinson's disease,PD
AE1_24652679_1_1 SS1_24652679_1_1 SS2_24652679_1_1 abbreviatedTo Leucine-rich repeat kinase 2,LRRK2
AE1_24652679_2_0 SS1_24652679_2_0 SS2_24652679_2_0 abbreviatedTo progranulin,PGRN
AE1_24652679_5_0 SS1_24652679_5_0 SS2_24652679_5_0 abbreviatedTo matrix metalloprotease,MMP

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-155 DRI_Background denotes Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
T2 156-316 DRI_Background denotes Increasing evidence suggests that Parkinson's disease (PD)-linked Leucine-rich repeat kinase 2 (LRRK2) has a role in peripheral and brain-resident immune cells.
T3 317-478 DRI_Background denotes Furthermore, dysregulation of the anti-inflammatory, neurotrophic protein progranulin (PGRN) has been demonstrated in several chronic neurodegenerative diseases.
T4 479-755 DRI_Outcome denotes Here we show that PGRN levels are significantly reduced in conditioned medium of LRRK2(R1441G) mutant mouse fibroblasts, leukocytes, and microglia, whereas levels of proinflammatory factors, like interleukin-1β and keratinocyte-derived chemokine, were significantly increased.
T5 756-856 DRI_Background denotes Decreased PGRN levels were also detected in supernatants of cultured human fibroblasts isolated from
T6 857-877 Token_Label.OUTSIDE denotes presymptomatic LRRK2
T7 877-949 DRI_Background denotes (G2019S) mutation carriers, while mitochondrial function was unaffected.
T8 950-1080 DRI_Background denotes Furthermore, medium levels of matrix metalloprotease (MMP) 2 increased, whereas MMP 9 decreased in LRRK2(R1441G) mutant microglia.
T9 1081-1262 DRI_Outcome denotes Increased proteolytic cleavage of the MMP substrates ICAM-5 and α-synuclein in synaptoneurosomes from LRRK2(R1441G) mutant mouse brain indicates increased net synaptic MMP activity.
T10 1263-1319 DRI_Background denotes PGRN levels were decreased in the cerebrospinal fluid of
T11 1320-1340 Token_Label.OUTSIDE denotes presymptomatic LRRK2
T12 1341-1421 DRI_Background denotes mutant mice, whereas PGRN levels were increased in aged symptomatic mutant mice.
T13 1422-1595 DRI_Background denotes Notably, PGRN levels were also increased in the cerebrospinal fluid of PD patients carrying LRRK2 mutations, but not in idiopathic PD patients and in healthy control donors.
T14 1596-1786 DRI_Outcome denotes Our data suggest that proinflammatory activity of peripheral and brain-resident immune cells may particularly contribute to the early stages of Parkinson's disease caused by LRRK2 mutations.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 156-316 DRI_Background denotes Increasing evidence suggests that Parkinson's disease (PD)-linked Leucine-rich repeat kinase 2 (LRRK2) has a role in peripheral and brain-resident immune cells.
T2 317-478 DRI_Background denotes Furthermore, dysregulation of the anti-inflammatory, neurotrophic protein progranulin (PGRN) has been demonstrated in several chronic neurodegenerative diseases.
T3 479-755 DRI_Outcome denotes Here we show that PGRN levels are significantly reduced in conditioned medium of LRRK2(R1441G) mutant mouse fibroblasts, leukocytes, and microglia, whereas levels of proinflammatory factors, like interleukin-1β and keratinocyte-derived chemokine, were significantly increased.
T4 756-856 DRI_Background denotes Decreased PGRN levels were also detected in supernatants of cultured human fibroblasts isolated from
T5 877-949 DRI_Background denotes (G2019S) mutation carriers, while mitochondrial function was unaffected.
T6 950-1080 DRI_Background denotes Furthermore, medium levels of matrix metalloprotease (MMP) 2 increased, whereas MMP 9 decreased in LRRK2(R1441G) mutant microglia.
T7 1081-1262 DRI_Outcome denotes Increased proteolytic cleavage of the MMP substrates ICAM-5 and α-synuclein in synaptoneurosomes from LRRK2(R1441G) mutant mouse brain indicates increased net synaptic MMP activity.
T8 1263-1319 DRI_Background denotes PGRN levels were decreased in the cerebrospinal fluid of
T9 1341-1421 DRI_Background denotes mutant mice, whereas PGRN levels were increased in aged symptomatic mutant mice.
T10 1422-1595 DRI_Background denotes Notably, PGRN levels were also increased in the cerebrospinal fluid of PD patients carrying LRRK2 mutations, but not in idiopathic PD patients and in healthy control donors.
T11 1596-1786 DRI_Outcome denotes Our data suggest that proinflammatory activity of peripheral and brain-resident immune cells may particularly contribute to the early stages of Parkinson's disease caused by LRRK2 mutations.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
24652679-1#66#94#gene120892 222-250 gene120892 denotes Leucine-rich repeat kinase 2
24652679-1#96#101#gene120892 252-257 gene120892 denotes LRRK2
24652679-1#34#53#diseaseC0030567 190-209 diseaseC0030567 denotes Parkinson's disease
24652679-1#55#57#diseaseC0030567 211-213 diseaseC0030567 denotes PD
24652679-1#34#53#diseaseC0030567 190-209 diseaseC0030567 denotes Parkinson's disease
24652679-1#55#57#diseaseC0030567 211-213 diseaseC0030567 denotes PD
24652679-2#74#85#gene2896 391-402 gene2896 denotes progranulin
24652679-2#87#91#gene2896 404-408 gene2896 denotes PGRN
24652679-2#134#160#diseaseC0524851 451-477 diseaseC0524851 denotes neurodegenerative diseases
66#94#gene12089234#53#diseaseC0030567 24652679-1#66#94#gene120892 24652679-1#34#53#diseaseC0030567 associated_with Leucine-rich repeat kinase 2,Parkinson's disease
66#94#gene12089255#57#diseaseC0030567 24652679-1#66#94#gene120892 24652679-1#55#57#diseaseC0030567 associated_with Leucine-rich repeat kinase 2,PD
66#94#gene12089234#53#diseaseC0030567 24652679-1#66#94#gene120892 24652679-1#34#53#diseaseC0030567 associated_with Leucine-rich repeat kinase 2,Parkinson's disease
66#94#gene12089255#57#diseaseC0030567 24652679-1#66#94#gene120892 24652679-1#55#57#diseaseC0030567 associated_with Leucine-rich repeat kinase 2,PD
96#101#gene12089234#53#diseaseC0030567 24652679-1#96#101#gene120892 24652679-1#34#53#diseaseC0030567 associated_with LRRK2,Parkinson's disease
96#101#gene12089255#57#diseaseC0030567 24652679-1#96#101#gene120892 24652679-1#55#57#diseaseC0030567 associated_with LRRK2,PD
96#101#gene12089234#53#diseaseC0030567 24652679-1#96#101#gene120892 24652679-1#34#53#diseaseC0030567 associated_with LRRK2,Parkinson's disease
96#101#gene12089255#57#diseaseC0030567 24652679-1#96#101#gene120892 24652679-1#55#57#diseaseC0030567 associated_with LRRK2,PD
74#85#gene2896134#160#diseaseC0524851 24652679-2#74#85#gene2896 24652679-2#134#160#diseaseC0524851 associated_with progranulin,neurodegenerative diseases
87#91#gene2896134#160#diseaseC0524851 24652679-2#87#91#gene2896 24652679-2#134#160#diseaseC0524851 associated_with PGRN,neurodegenerative diseases